Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoliflodacin PK/Safety in Healthy Subjects
NCT03404167Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zoliflodacin in gonorrhea, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Maximum Observed Concentration, Time of Maximum Observed Concentration and 5 more. Started Feb 2018; status: completed.
02
Drugs
zoliflodacin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT03404167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03404167.